Cell Culture & Bioprocessing:

Getting cell therapy products onto the market as quickly as possible still remains a key driver in the improve of recombinant therapeutic proteins. Any such advance in bioprocessing is of particular interest to the industry if it considerably shortens the development timeline or improves the end product. In the monoclonal antibody (MAb) area, platform procedures have allowed companies to regulate on particular mammalian cell lines, transfection approaches, process conditions and also downstream processing to shorten the development timeline.

  • Nano methods to target cancer cells
  • Nano micro fluids in cell therapy
  • Nano materials and nano engineering
  • Nano vaccines
  • Pros & cons of molecular manufacturing

Related Conference of Cell Culture & Bioprocessing:

Cell Culture & Bioprocessing: Conference Speakers